jRCT2031240539招募中不适用
Post-marketing surveillance of AVIGAN tablets 200mg (All-Case Surveillance) - Severe Fever with Thrombocytopenia Syndrome -
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 340
- 主要终点
- -
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- No limit 至 No limit（—）
- 性别
- All
入选标准
- •All patients treated with AVIGAN tablets 200 mg
排除标准
- 未提供
结局指标
主要结局
-
Incidence of adverse drug reactions Incidence of serious adverse events
次要结局
- Mortality rate (by patient demographics and disease characteristics)(at the time of discontinuation of AVIGAN tablets 200 mg or discharge (including death), cumulative mortality rate up to Day 28 after the start of administration)
研究者
相似试验
招募中
不适用
Post-marketing clinical study of AVIGAN tablets 200mg (SFTS)jRCT2061240089FUJIFILM Toyama Chemical Co., Ltd.50
招募中
不适用
Post-marketing surveillance of AMYViD InjectioVisualization of amyloid beta plaque in the brain of patients with cognitive dysfunction suspected oJPRN-jRCT2031220067Kazunori Bando500
招募中
Unknown
VANFLYTA Tablet Post-marketing Surveillance StudyRelapsed or refractory acute myeloid leukemia with FLT3-ITD mutation positiveJPRN-jRCT1080224910DAIICHI SANKYO CO., LTD.210
招募中
Unknown
All case study of Lenvima Capsulenresectable thyroid cancerJPRN-jRCT1080222856Eisai Co., Ltd.400
未知
Unknown
Post-marketing surveillance of administration of botulinum toxin type B(NerBloc)-investigation of the clinical condition in patients with changing from botulinum toxin type Acervical dystoniaJPRN-jRCT1080222128Eisai Co., Ltd.150